ABC  Vol.3 No.3 A , June 2013
Different effects of the inhibition of Src activity on Akt/PKB in melanoma cells with wild BRAF and mutated BRAF V600E
Abstract: Src regulates cell adhesion, invasiveness, motility and growth in cancer cells. In melanoma, accumulating data show that Src inhibition can be effective and may enhance the effects of other agents. Increased Src expression and activity thus has recently become a target for drug therapy. Several melanoma cell lines were exposed to inhibitors of Src activity despite their broad specificity. To examine the particular activity of Src in human melanoma cells, we used SU6656, the selective inhibitor of Src family protein kinases. The activity of Src and cell proliferation were suppressed in HBL human cells, wild type melanoma cells and in SK-MEL-5 human melanoma cells harboring mutant BRAF V600E, upon their treatment with SU6656. The suppression of Src kinase activity had not inhibitory effects on Akt/PKB activity in SK-MEL-5 cells, which we have previously found in HBL cells. This may indicate that changes of Src involvement in the control of Akt/PKB activity and its downstream signaling could be induced by BRAF V600E mutation in SK-MEL-5 cells.
Cite this paper: Tuháčková, Z. , Réda, J. , Ondrušová, L. and Žáková, P. (2013) Different effects of the inhibition of Src activity on Akt/PKB in melanoma cells with wild BRAF and mutated BRAF V600E. Advances in Biological Chemistry, 3, 6-11. doi: 10.4236/abc.2013.33A002.

[1]   Chen, X.G., Liu, F., Song, X.F., Wang, Z.H., Dong, Z.Q., Hu, Z.Q., et al. (2010) Rapamycin regulates Akt and ERK phosphorylation through mTORC1 and mTORC2 signaling pathways. Molecular Carcinogenesis, 49, 603610. doi:10.1002/mc.20628

[2]   Laplante, M. and Sabatini, D.M. (2012) mTOR signaling in growth control and disease. Cell, 149, 274-293. doi:10.1016/j.cell.2012.03.017

[3]   Yang, H., Higgins, B., Kolinsky, K., Packman, K., Bradley, W.D., Lee, R.J., et al. (2012) Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer. Cancer Research, 72, 779-789. doi:10.1158/0008-5472.CAN-11-2941

[4]   Hatzivassiliou, G., Song, K., Yen, I., Brandhuber, B.J., Anderson, D.J., Alvarado, R., et al. (2010) RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature, 464, 431-435. doi:10.1038/nature08833

[5]   Bollag, G., Hirth, P., Tsai, J., Zhang, J., Ibrahim, P.N., Cho, H., et al. (2010) Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature, 467, 596-599. doi:10.1038/nature09454

[6]   Shao, Y. and Aplin, A.E. (2010) Akt3-mediated resistance to apoptosis in B-RAF-targeted melanoma cells. Cancer Research, 70, 6670-6681. doi:10.1158/0008-5472.CAN-09-4471

[7]   Ceol, C.J., Houvras, Y., Jane-Valbuena, J., Bilodeau, S., Orlando, D.A., Battisti, V., et al. (2011) The histone methyltransferase SETDB1 is recurrently amplified in melanoma and accelerates its onset. Nature, 471, 513-517. doi:10.1038/nature09806

[8]   Su, F., Bradley, W.D., Wang, Q., Yang, H., Xu, L., Higgins, B., et al. (2012) Resistance to selective BRAF inhibition can be mediated by modest upstream pathway activation. Cancer Research, 72, 969-978. doi:10.1158/0008-5472.CAN-11-1875

[9]   Ondrusová, L., Réda, J., Záková, P. and Tuhácková, Z. (2013) Inhibition of mTORC1 by SU6656, the selective Src kinase inhibitor is not accompanied by activation of Akt/ PKB signaling in melanoma cells. Folia Biologica, 59.

[10]   Blake, R.A., Broome, M.A., Liu X., Wu, J., Gishizky, M., Sun, L., et al. (2000) SU6656, a selective src family kinase inhibitor, used to probe growth factor signaling. Molecular and Cellular Biology, 20, 9018-9027. doi:10.1128/MCB.20.23.9018-9027.2000

[11]   Vachtenheim, J., Novotná, H. and Ghanem, G. (2001) Transcriptional repression of the microphthalmia gene in melanoma cells correlates with the unresponsiveness of target genes to ectopic microphthalmia-associated transcription factor. The Journal of Investigative Dermatology, 117, 1505-1511. doi:10.1046/j.0022-202x.2001.01563.x

[12]   Vojtěchová, M., Turecková, J., Kucerová, D., Sloncová, E., Vachtenheim, J. and Tuhácková, Z. (2008) Regulation of mTORC1 signaling by Src kinase activity is Akt1independent in RSV-transformed cells. Neoplasia, 10, 99107. doi:10.1593/neo.07905

[13]   Kumar, S.M., Yu, H., Edwards, R., Chen, L., Kazianis, S., Brafford, P., et al. (2007) Mutant V600E BRAF increases hypoxia inducible factor-1α expression in melanoma. Cancer Research, 67, 3177-3184. doi:10.1158/0008-5472.CAN-06-3312

[14]   Zheng, B., Jeong, J.H., Asara, J.M., Yuan,Y.Y., Granter, S.R., Chin, L., et al. (2009) Oncogenic B-RAF negatively regulates the tumor suppressor LKB1 to promote melanoma cell proliferation. Molecular Cell, 33, 237-247. doi:10.1016/j.molcel.2008.12.026

[15]   Poulikakos, P.I., Zhang, C., Bollag, G., Shokat, K.M., Rosen, N., et al. (2010) RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature, 464, 427-430. doi:10.1038/nature08902

[16]   Villanueva, J., Vultur, A., Lee, J.T., Somasundaram, R., Fukunaga-Kalabis, M., Cipolla, A.K., et al. (2010) Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell, 18, 683695. doi:10.1016/j.ccr.2010.11.023

[17]   Ferguson, J., Arozarena, I., Ehrhardt, M., Wellbrock, C. et al. (2013) Combination of MEK and SRC inhibition suppresses melanoma cell growth and invasion. Oncogene, 32, 86-96. doi:10.1038/onc.2012.25

[18]   Girotti, M.R., Pedersen, M., Sanchez-Laorden, B., Viros, A., Turajlic, S., Niculescu-Duvaz, D., et al. (2013) Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma. Cancer Discovery, 3, 158-167. doi:10.1158/2159-8290.CD-12-0386

[19]   Niu, G., Bowman, T., Huang, M., Shivers, S., Reintgen, D., Daud, A., et al. (2002) Roles of activated Src and Stat3 signaling in melanoma tumor cell growth. Oncogene, 21, 7001-7010. doi:10.1038/sj.onc.1205859

[20]   Homsi, J., Cubitt, C. and Daud, A. (2007) The Src signaling pathway: A potential target in melanoma and other malignancies. Expert Opinion Therapeutic Targets, 11, 91-100. doi:10.1517/14728222.11.1.91

[21]   Homsi, J., Cubitt, C.L., Zhang, S., Munster, P.N., Yu, H., Sullivan, D.M., et al. (2009) Src activation in melanoma and Src inhibitors as therapeutic agents in melanoma. Melanoma Research, 19, 167-175. doi:10.1097/CMR.0b013e328304974c

[22]   Ribas, A., Hersey, P., Middleton, M.R., Gogas, H., Flaherty, K.T., Sondak, V.K., et al. (2012) New challenges in endpoints for drug development in advanced melanoma. Clinical Cancer Research, 18, 336-341. doi:10.1158/1078-0432.CCR-11-2323

[23]   Wu, W., Sun, Z., Wu, J., Peng, X., Gan, H., Zhang, C., et al. (2012) Trihydrophobin 1 phosphorylation by c-Src regulates MAPK/ERK signaling and cell migration. PLoS One, 7, e29920. doi:10.1371/journal.pone.0029920

[24]   Eustace, A.J., Crown, J., Clynes, M., ODonovan, N., et al. (2008) Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines. Journal of Translational Medicine, 6, 53-56. doi:10.1186/1479-5876-6-53

[25]   Jin, W., Yun, C., Hobbie, A., Martin, M.J., Sorensen, P.H., Kim, S.J., et al. (2007) Cellular transformation and activation of the phosphoinositide-3-kinase-Akt cascade by the ETV6-NTRK3 chimeric tyrosine kinase requires c-Src. Cancer Research, 67, 3192-3200. doi:10.1158/0008-5472.CAN-06-3526